Johnson & Johnson has initiated legal action against divisions of Cigna, alleging that the health insurer collaborated with a drug-benefit middleman to deplete the company's copay assistance funds. This financial assistance is crucial for patients using some of Johnson & Johnson's higher-priced medications. The lawsuit follows a recent order for Johnson & Johnson to pay $1 billion to Auris Health shareholders and founders, including Lux Capital, stemming from a lawsuit similar to one involving Bristol Myers Squibb and Padlock Therapeutics. Separately, Gilead Sciences has filed a lawsuit against a pharmacy and health insurer, accusing them of compelling American patients to fill prescriptions with non-FDA-approved medicines imported from Turkey.